ESTRO 2024 - Abstract Book

S2234

Clinical - Upper GI

ESTRO 2024

SBRT resulted in durable LC, extended PFS and promising survival rates in both OP and OM liver disease, particularly when dose intensive regimens are delivered (i.e. BED >100Gy) in non-heavily pretreated patients. Furthermore, the use of abdominal compression assisted VMAT was not inferior to fiducial based real time tumor tracking RRT.

Further studies are needed to harmonize dose prescription in SBRT in liver metastases, in order to assess its impact on overall disease control and survival.

Keywords: SBRT, LIVER METASTASIS, OLIGOMETASTATIC